<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="189953">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620451</url>
  </required_header>
  <id_info>
    <org_study_id>AT1001-011</org_study_id>
    <nct_id>NCT00620451</nct_id>
  </id_info>
  <brief_title>Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate (AT-1001) in Active Celiac Disease</brief_title>
  <official_title>A Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease With AT-1001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alba Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alba Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to look at how effective and safe larazotide acetate
      (AT-1001) is when it is given to subjects who have active Celiac Disease. A &quot;leaky gut&quot; is
      often found in Celiac Disease patients, and it is thought that the leakiness contributes to
      the disease, possibly by letting more gluten enter the body. Larazotide acetate (AT-100l) is
      an experimental drug that may possibly reduce gut leakiness and is being investigated to see
      if it can help people with Celiac disease along with a gluten free diet.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an outpatient, randomized, parallel-group, double-blind, multicenter, 8-week
      study with the following treatment arms:

        1. larazotide acetate (AT-1001) 4 mg (three times a day)

        2. larazotide acetate (AT-1001) 8 mg (three times a day)

        3. placebo (three times a day)

      Subjects will be required to have a baseline/screening biopsy and a follow-up biopsy at Day
      56. Subjects will be required to adhere to a gluten free diet for the duration of the study.

      Primary Outcome:

      * To assess the efficacy of larazotide acetate (AT-1001) versus placebo in inducing
      remission in subjects with active Celiac Disease. Improvement is defined by changes (Villous
      Height to Crypt Depth (Vh:Cd) ratio),measured by duodenal-jejunal biopsy.

      Secondary Outcome:

      *To assess safety and tolerability of larazotide acetate (AT-1001) in subjects with active
      Celiac Disease.

      Estimated Enrollment 106 subjects Estimated Study Start Date: February 2008 Estimated Study
      Completion Date: December 2009
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Villous Height to Crypt Depth (Vh:Cd) ratio</measure>
    <time_frame>Baseline and at Day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of larazotide acetate (AT-1001)</measure>
    <time_frame>From Randomization to Follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>larazotide acetate (AT-1001)</intervention_name>
    <description>4 mg three times a day for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>larazotide acetate (AT-1001)</intervention_name>
    <description>8 mg three times a day for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo three times a day for 8 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age is 18 to 75 years, inclusive

          -  Female subjects should be post-menopausal, surgically sterile or women of child
             bearing potential with a negative serum beta hCG pregnancy test

          -  Is diagnosed with Celiac Disease by duodenal/jejunal biopsy or by capsule endoscopy
             plus positive anti-tTG

          -  Is willing to comply with a gluten-free diet for the duration of the study

        Exclusion Criteria:

          -  Has Refractory Celiac Disease or sever complications of Celiac Disease (e.g.
             Enteropathy-associated T cell Lymphoma - EATL-, ulcerative jejunitis, perforation)

          -  Is suspected to have lymphoma or any other serious complication of Celiac Disease

          -  Has chronic active GI disease other than Celiac Disease

          -  Has diabetes (Type 1 or Type 2) or other autoimmune disease that might interfere with
             the conduct of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Leon, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Alba Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Torrington</city>
        <state>Connecticut</state>
        <zip>06790</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Michigan</state>
        <zip>48047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Harrisburg</city>
        <state>North Carolina</state>
        <zip>28075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Gallipolis</city>
        <state>Ohio</state>
        <zip>45631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Paoli</city>
        <state>Pennsylvania</state>
        <zip>19301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Abbotsford</city>
        <state>British Columbia</state>
        <zip>V5ZIH2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y2H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4B3PB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Huesca</city>
        <zip>22004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Leon</city>
        <zip>24005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Reus</city>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Study Site</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.albatherapeutics.com</url>
    <description>Sponsors web site. Click here to learn more about the AT-1001</description>
  </link>
  <reference>
    <citation>Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther. 2007 Sep 1;26(5):757-66.</citation>
    <PMID>17697209</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <lastchanged_date>July 12, 2012</lastchanged_date>
  <firstreceived_date>February 7, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment</keyword>
  <keyword>Active</keyword>
  <keyword>Celiac</keyword>
  <keyword>Remission</keyword>
  <keyword>Induction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
